Real-Life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION - Full Text View

Real-Life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION (REVORUTION)

This study has been completed.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00526721

Purpose

To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration

Condition

Hypercholesterolemia

Genetics Home Reference related topics:

hypercholesterolemia

MedlinePlus related topics:

Cholesterol

ChemIDplus related topics:

Rosuvastatin Rosuvastatin calcium

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective

Official Title:	An Observational, Non-Interventional, Multi-Center Study to Evaluate Efficacy and Tolerability of High Dose Rosuvastatin in High Risk Patients After Titration

Further study details as provided by AstraZeneca:

Estimated Enrollment:	2136
Study Start Date:	August 2007
Study Completion Date:	April 2008
Primary Completion Date:	October 2007 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

High-risk hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on the physician's clinical decision and fulfill the following criteria
1. Over 18 years of age
2. Have history of CHD or CHD risk equivalents, such as peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease (TIA or stroke of carotid origin or >50% obstruction of carotid artery), DM, and 2+ risk factors with 10-year risk CHD>20%

Exclusion Criteria:

Patients already taking other hyperlipidemic agents
Patients who do not fulfil the indication criteria for statin therapy
Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00526721

Locations


Korea, Republic of, Jongro-gu
	Research Site
	Seoul, Jongro-gu, Korea, Republic of

Korea, Republic of, Kangnam-gu
	Research Site
	Seoul, Kangnam-gu, Korea, Republic of

Korea, Republic of, Songpa-gu
	Research Site
	Seoul, Songpa-gu, Korea, Republic of

Sponsors and Collaborators

AstraZeneca

Investigators


Study Director:	Hyunah Caroline Choi	AstraZeneca Korea

More Information

Related Info This link exits the ClinicalTrials.gov site

Study ID Numbers:	NIS-CKR-CRE-2007/6
First Received:	September 5, 2007
Last Updated:	October 14, 2008
ClinicalTrials.gov Identifier:	NCT00526721
Health Authority:	Korea:

Keywords provided by AstraZeneca:

Hypercholesterolemia

Crestor

LDL target goal

high risk patients

Naturalistic

Observational

Study placed in the following topic categories:

Rosuvastatin

Metabolic Diseases

Hyperlipidemias

Metabolic disorder

Hypercholesterolemia

Dyslipidemias

Lipid Metabolism Disorders

Additional relevant MeSH terms:

Antimetabolites

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Antilipemic Agents

Enzyme Inhibitors

Anticholesteremic Agents

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 16, 2008